April 29, 2026 a 07:43 pm
BDX: Fundamental Ratio Analysis - Becton, Dickinson and Company
Becton, Dickinson and Company operates in the healthcare sector, providing a wide range of medical supplies and devices. As a leader in medical technology, the company consistently demonstrates resilience and innovation in its field. Investors may find BDX's stable position and broad product portfolio promising, although market dynamics in the medical supply industry can influence its performance.
Fundamental Rating
The fundamental rating of BDX is strong, reflected in a diversified score profile.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 3 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 3 | |
| Price to Book | 3 |
Historical Rating
The historical performance of BDX shows consistent scores in various fundamental metrics.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-04-29 | 3 | 5 | 3 | 4 | 1 | 3 | 3 |
| Previous | 0 | 5 | 3 | 4 | 1 | 3 | 3 |
Analyst Price Targets
Analyst estimates and price targets for BDX suggest a steady valuation with potential upside.
| High | Low | Median | Consensus |
|---|---|---|---|
| $202 | $159 | $168.01 | $172.85 |
Analyst Sentiment
The analyst sentiment maintains a positive outlook, with a strong consensus towards a 'Buy' rating.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 16 | |
| Hold | 16 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Becton, Dickinson and Company stands out as a major player in the healthcare sector with robust fundamentals. While its debt levels present a potential risk, the overall strong performance across various financial metrics supports its growth potential. The positive analyst sentiment enhances its attractiveness, although market fluctuations and external economic factors remain risks. Investors may consider BDX for its stability and innovation in medical technologies, balancing these factors against broader market risks.